Full Count: Having Sired Twin Failures Hivid and Invirase, Roche Tempts Fate With High Profile T-20 Launch
Having Sired Twin Failures Hivid and Invirase, Roche Tempts Fate With High Profile T-20 Launch By Rob Camp and Matt Sharp Rapacious Returns "If 12,000 people were to take Fuzeon at $20,000, Roche would reap about $240M in revenues. By…